Service Information

The journey starts for us by identifying medicines with high unmet medical need but challenges in making them available to patients on a global or regional basis. This has resulted in Clinigen acquiring global or regional rights to essential medicines like:

CARDIOXANE® (dexrazoxane)
ETHYOL® (amifostine)
FOSCAVIR® (foscarnet sodium)
SAVENE® (dexrazoxane)
TOTECT® (dexrazoxane)

We can also partner with manufacturers to hold their licenses locally in Asia, Australasia and Africa.

Unique

  • We are a pharmaceutical and services company uniquely positioned to provide comprehensive lifecycle patient access solutions for clinical trials, unlicensed and licensed medicines.
  • Product revitalisation is driven by comprehensive supply, regulatory and global marketing expertise. This means we can take on a medicine in its entirety – giving our partners the opportunity to divest to a single, responsible new owner with the ability to distribute globally.
  • We provide a comprehensive global solution and are experienced in carrying out product acquisitions ensuring a rapid and effective transaction for our partners.

Ethical

  • We maintain access and uphold a product’s reputation by ensuring a consistent supply of the critical medicines that patients rely on.
  • The revitalisation strategy of our products is driven by the needs of physicians and patients and we supply directly to hospitals or through trusted partners to protect the supply chain.

Global

  • We have a unique global capability, operating anywhere in the world, in both licensed and unlicensed markets.

Key Facts

5

Clinigen owned medicines

100+

actively marketed licensed products